Last reviewed · How we verify
NCT05447845
Rapid Computerized Visual Acuity Test
trial testing Computerized visual acuity assessment program in Vision Disorders in 200 participants. Status unknown.
31 October 2022
Quick facts
| Lead sponsor | Rambam Health Care Campus |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2019 |
| Primary completion | 31 October 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Computerized visual acuity assessment program
Conditions studied
- Vision Disorders — all drugs for Vision Disorders →
- Refractive Errors — all drugs for Refractive Errors →
- Retinal Disease — all drugs for Retinal Disease →
- Cataract — all drugs for Cataract →
Sponsor
Rambam Health Care Campus — full company profile →
Who can join
Adults 18 to 120, any sex, with Vision Disorders or Refractive Errors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A novel computerized visual acuity test was developed and tested on both healthy persons and patients with ocular conditions. Visual acuity outcomes of the computerized test will be compared to the Early Treatment Diabetic Retinopathy Study (ETDRS) in measures of reproducibility, accuracy and numbers of questions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05447845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vision Disorders
Currently open trials in the same condition.
- NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
- NCT06992622 — Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis · recruiting
- NCT06451172 — Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis · EARLY_PHASE1 · recruiting
- NCT04123626 — A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due · Phase 1, PHASE2 · active not recruiting
- NCT02911805 — Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation · NA · active not recruiting
Other Rambam Health Care Campus trials
Trials by the same sponsor.
- NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
- NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
- NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
- NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
- NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05447845 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
- Last refreshed: 7 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05447845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing